Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
May 28, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative,...
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
May 15, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial...
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 08:50 ET
|
Atossa Therapeutics, Inc.
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with...
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
May 07, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services...
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
April 29, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore...
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
April 15, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new...
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
April 11, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at...
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
April 09, 2024 11:59 ET
|
Atossa Therapeutics, Inc.
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2...
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
April 01, 2024 16:00 ET
|
Atossa Therapeutics, Inc.
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase 2 EVANGELINE study...
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
March 19, 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human...